Novel versus conventional vitamin D2 supplementation protocol for correcting and retaining hypovitaminosis D after fragility hip fracture: A prospective, randomized, controlled trial

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220725002

Enrollment

170

Registered

2022-07-25

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypovitaminosis D in fragility hip fracture patient Vitamin D2, Hypovitaminosis D, Hip fracture, Fragility hip fracture

Interventions

Vitamin D2 (Ergocalciferol) 20,000 IU will be prescribed for the participant to take 1 capsule (20,000 IU) following or with the morning meal in the designated days which will be stratified according

Active Comparator Dietary Supplement,Active Comparator Dietary Supplement

Novel vitamin D2 supplement protocol,Conventional vitamin D2 supplement protocol

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients over 50 years old 2. Diagnosed with hip fracture (fracture neck of femur or fracture intertrochanter of femur) from a minor accident (simple fall from standing height or lower)

Exclusion criteria

Exclusion criteria: 1. Patients who previously have received vitamin D supplements 2. patients with hypercalcemia (corrected serum calcium > 10.5 mg/dL) 3. Patients with impaired renal function (eGFR < 30 mL/min/1.73m 2 ). 4. Patients with abnormal liver function (ALT or AST > 2x of upper normal limit). 5. Other pathologic fracture confirmed by pathological reports 6. Patients receiving anticonvulsants 7. Patients with problems absorbing nutrients (short bowel syndrome, inflammatory bowel disease). 8. Patients with chronic granulomatous disease 9. Patients with multiple fractures in this visit

Design outcomes

Primary

Measure	Time frame
Patient whose serum 25(OH)D level was greater than or equal to 30 ng/mL at 1 month after received vitamin D2 supplement protocol Percent	—

Secondary

Measure	Time frame
Serum 25(OH)D at 1 and 3 months after supplement protocol serum level,patient whose serum 25(OH)D level was greater than or equal to 30 ng/mL at 3 months after supplemnent protocol Percentage,Serum calcium at 1 and 3 months after supplement protocol serum level,Subject with hypercalcemia 1 and 3 months after supplement protocol number,Subject with symptomatic hypercalcemia at 1 and 3 months after supplement protocol number of patient, patient reported questionaire, admission record,Serum phosphorus 1 and 3 months after supplement protocol serum level,Serum parathyroid hormone 1 and 3 months after supplement protocol serum level,Serum alkaline phosphatase 1 and 3 months after supplement protocol Serum level	—

Measure

Time frame

Serum 25(OH)D at 1 and 3 months after supplement protocol serum level,patient whose serum 25(OH)D level was greater than or equal to 30 ng/mL at 3 months after supplemnent protocol Percentage,Serum calcium at 1 and 3 months after supplement protocol serum level,Subject with hypercalcemia 1 and 3 months after supplement protocol number,Subject with symptomatic hypercalcemia at 1 and 3 months after supplement protocol number of patient, patient reported questionaire, admission record,Serum phosphorus 1 and 3 months after supplement protocol serum level,Serum parathyroid hormone 1 and 3 months after supplement protocol serum level,Serum alkaline phosphatase 1 and 3 months after supplement protocol Serum level

—

Countries

Thailand

Contacts

Public ContactNitchanant Kitcharanant

Chiang Mai University

nk_win@hotmail.com66871071133

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026